Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699633 | 0.91 | MAOB (0.52) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL28476407 | 0.90 | MAOB (0.51) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6386328 | 0.90 | MAOB (0.46) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL28970950 | 0.89 | MAOB (0.61) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6702208 | 0.88 | LMNA (0.56) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8070497 | 0.88 | MAOB (0.61) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL11237824 | 0.86 | CYP4F2 (0.62) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL10893534 | 0.84 | FFAR1 (0.66) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL2514457 | 0.83 | HIF1A (0.58) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8588173 | 0.83 | LMNA (0.58) | MAOBLMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108474892-B | Polarizing plate protective film, method for producing same, and polarizing plate | 柯尼卡美能达株式会社 | 2020-12-11 | — | — | CN | disclosed |
| EP-2243813-B1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING THE LIQUID CRYSTAL COMPOSITION | ADEKA CORP (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2243813-B1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING THE LIQUID CRYSTAL COMPOSITION | ADEKA CORP (JP) | 2015-11-04 | — | — | EP | disclosed |
| CN-101282922-B | Polymerizable liquid crystal compound having condensed ring, and homopolymer and copolymer of the polymerizable liquid crystal compound | ADEKA CORP | 2015-01-28 | — | — | CN | disclosed |
| US-8283000-B2 | Liquid crystal composition containing polymerizable compound and liquid crystal display using the liquid crystal composition | ADEKA CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-8283000-B2 | Liquid crystal composition containing polymerizable compound and liquid crystal display using the liquid crystal composition | ADEKA CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-8283000-B2 | Liquid crystal composition containing polymerizable compound and liquid crystal display using the liquid crystal composition | ADEKA CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-1813594-B1 | POLYMERIZABLE COMPOUND AND COMPOSITION CONTAINING THE POLYMERIZABLE COMPOUND | ADEKA CORP (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20100328601-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL DISPLAY USING THE LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100328601-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL DISPLAY USING THE LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2003072102-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6610696-B2 | Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1313715-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY & COMPANY LILY CORPORATE CENTER (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2001016120-A9 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6417212-B1 | PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS | ELI LILLY & COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2002018355-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, PPARA, PPARD | MAOB 3185/4885LMNA 1897/4885CYP1A2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.